Clinical trials: Hepatobiliary Disease
End-stage Liver Disease
Conditioning With Volatile Anesthetics in Liver Transplantation
The gap between the number of candidates for orthotopic liver transplantation and the availability of suitable liver grafts has led to a rise in deaths on most waiting lists.
- Trial name
- NCT00913276
- Testing
- Propofol, Sevoflurane
- Where
- Switzerland
- Volunteers
- 98 people
- Sponsor
- University of Zurich
Cirrhosis, PTSD
Microbiome Modulation With Prebiotics in PTSD and Cirrhosis
Despite medical advancements, PTSD remains a major issue in Veterans1. Current treatment strategies have relatively poor adherence.
- Trial name
- RESIST-PTSD (NCT06464952)
- Testing
- Resistant potato starch, Powdered cellulose
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Bariatric Surgery Candidate, Obesity, Morbid
Portal Hypetension and Bariatric Surgery (BARIAPORTAL)
The worldwide obesity epidemic has led to an increase in the proportion of patients with chronic liver disease due to non-alcoholic fatty liver disease (NAFLD) and in the prevalence of obesity in patients with cirrhosis of all…
- Conditions
- Bariatric Surgery Candidate, Obesity, Morbid, Portal Hypertension
- Trial name
- BARIAPORTAL (NCT05653115)
- Testing
- Bariatric surgery
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Morbid Obesity, Insulin Resistance
Assessment of Insulin Resistance, NAFLD, Predictors of CV Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass Surgery
The purpose of this research is to further study the effect weight loss after gastric bypass surgery has on the heart and blood pressure and on how the body uses or metabolizes the sugars, fats and proteins we eat.
- Conditions
- Morbid Obesity, Insulin Resistance, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT01007955
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Massachusetts, Worcester
Chronic HCV
Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation
The main purpose of this study is to determine whether psychological intervention is effective in improving quality of life, mood, and relationships among adults with hepatitis C virus and cirrhosis awaiting liver transplantation.
- Trial name
- NCT00794911
- Testing
- Quality of Life Therapy, Supportive Therapy
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Beth Israel Deaconess Medical Center
Non-Alcoholic Fatty Liver Disease
Effect of Molecular Hydrogen in Patients With NAFLD
Molecular hydrogen H2 acts as antioxidant which selectively reduces cytotoxic harmful reactive oxygen species ROS and concomitantly acts as biological messenger, which mediates several signaling pathways that play cytoprotective…
- Trial name
- EMoHyNAFLD (NCT05325398)
- Testing
- HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada
- Where
- Slovakia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Comenius University
Alcoholic Hepatitis
IL-1 Signal Inhibition in Alcoholic Hepatitis
Alcoholic hepatitis (AH) is a florid presentation of alcoholic liver disease characterized by liver failure in the context of recent and heavy alcohol consumption.
- Trial name
- ISAIAH (NCT03775109)
- Testing
- Canakinumab 150mg/ml solution for injection
- Where
- 16 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- Imperial College London
MAFLD in Prediabetes and Diabetes
Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance
Metabolic-dysfunction-associated fatty liver disease (MAFLD) has evolved as a major health problem recently. Discovering ways to prevent or delay the progression of MAFLD has become a global focus.
- Trial name
- SGLT2 (NCT07891234)
- Testing
- Dapagliflozin 5Mg Tab, Metfomin 500 mg, Dapagliflozin (10mg Tab)
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Sherihan AboElyazed Mohamed Khalil
NAFLD
Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)
The aim of this study is to test a non-invasive imaging technique to reliably diagnose NAFLD in children and adolescents with obesity and assess the degree of fibrosis.
- Trial name
- NAFLD (NCT03587298)
- Testing
- Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- RWTH Aachen University
Non Alcoholic Steatohepatitis
Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
The study was being conducted in order to assess the pharmacokinetics and the safety of elafibranor following once daily administration of two dose levels of elafibranor (80 milligrams [mg] and 120mg) during 3 months in children…
- Trial name
- NCT03883607
- Testing
- Elafibranor 80mg, Elafibranor 120mg
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Genfit
Fatty Liver Without Mention of Alcohol
A Clinical Study of Curcuvail® in Patients With Non-alcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. It comprises a wide spectrum of disorders that range from simple steatosis to nonalcoholic steatohepatitis (NASH), advanced fibrosis…
- Trial name
- NAFLD (NCT06256926)
- Testing
- Test Product: Curcuvail® 250mg capsule (Curcuma longa Extractcontaining 35% Curcuminoids)
- Where
- India
- Volunteers
- 30 people
- Sponsor
- COD Research Private Ltd
Metabolic Dysfunction-Associated Steatotic Liver Disease, People Living With HIV
Effect on Body Weight Reduction of a Behavioral Intervention on Lifestyle Using a Digital Nutritional Program in People Living With HIV and Metabolic Dysfunction-associated Steatotic Liver Disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease in people living with HIV (PLWH). Currently, there are no approved medications to treat this condition.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, People Living With HIV, Life Style
- Trial name
- APEVI (NCT07456332)
- Testing
- Digital nutritional program, Standard care dietary and exercice advice.
- Where
- Spain
- Volunteers
- 116 people
- Sponsor
- Hospital Universitari de Bellvitge
Chronic Hepatitis c, Cirrhosis, Liver
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated interferon) in patients who failed to respond to…
- Conditions
- Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
- Trial name
- HALT-C (NCT00006164)
- Testing
- Peginterferon alfa-2a + Ribavirin, Peginterferon alfa-2a
- Where
- 11 sites in United States
- Volunteers
- 1,050 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ALD - Alcoholic Liver Disease
Comparison of ALD, NASH, and Healthy Control Patients
The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy controls and non-drinking healthy controls, is an essential first step in…
- Trial name
- NCT03224949
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Liver Cancer (Primary and Metastatic)
A Cohort Study (Risk Prediction of HCC in Patients With Chronic Liver Disease)
Evaluating the effectiveness of standardized HCC risk stratification management in improving early diagnosis rates in patients with chronic liver disease
- Trial name
- NCT07820644
- Where
- China
- Volunteers
- 15,000 people
- Sponsor
- Cai Qingxian
NASH - Nonalcoholic Steatohepatitis
Spironolactone Therapy In Young Women With NASH
Nonalcoholic steatohepatitis (NASH), or fat-related liver inflammation and scarring is projected to be the leading cause of cirrhosis in the United States (U.S.) within the next few years.
- Trial name
- NCT03576755
- Testing
- Spironolactone 100mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Hepatic Insufficiency, Hypoalbuminemia
Mitochondrial Function in Patients With Severe Liver Disease
The researchers will recruit patients with liver disease at Parkland Hospital. Patients will fast overnight, and the next morning will receive an oral mixture of [U-13C3]glycerol (25 mg/kg) plus unlabeled glycerol (25 mg/kg).
- Trial name
- SLDglyc (NCT02457702)
- Testing
- Orally administered labeled glycerol
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Fatty Liver, Hepatitis
Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to determine if orlistat (Xenical) therapy in overweight patients with NASH leads to enhanced weight loss over time, with subsequent improvement in the underlying necroinflammatory and fibrotic…
- Trial name
- NCT00160407
- Testing
- Orlistat (Xenical), 1400 kcal diet (30% fat)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- St. Louis University
Obstructive Sleep Apnea, Non-alcoholic Fatty Liver Disease
Obstructive Sleep Apnoea and CPAP Treatment Response in Patients With Non-alcoholic Fatty Liver Disease
To study the frequency of obstructive sleep apnea (OSA) and continuous positive airway pressure (CPAP) treatment response in patients with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT02728765
- Testing
- Continuous positive airway pressure (CPAP)
- Where
- Hong Kong
- Volunteers
- 120 people
- Sponsor
- Chinese University of Hong Kong
Liver Diseases, Hepatocellular Cancer
Adult-to-Adult Living Donor Transplant Cohort Study
The study is being conducted for the following reasons: 1. To determine the prevalence, course, and predictors of poor Health Related Quality of Life (HRQOL) outcomes associated with living donor donation. 2.
- Conditions
- Liver Diseases, Hepatocellular Cancer, End Stage Liver Disease, Hepatitis C
- Trial name
- A2ALL-2 (NCT01619475)
- Where
- 9 sites in United States, Canada
- Volunteers
- 1,871 people
- Sponsor
- Arbor Research Collaborative for Health